← Mad Money w/ Jim Cramer
Mad Money w/ Jim Cramer
Mad Money w/ Jim Cramer 11/10/25
00:44:20
Listen to Jim Cramer’s personal guide through the confusing jungle of Wall Street investing, navigating through opportunities and pitfalls with one goal in mind - to help you make money. Mad Money Disclaimer
Loading summary
Transcript85 lines
- [00:00]
Commercial Announcer
Fidelity Active ETFs have the flexibility to shift and transform as markets do the same. So instead of just riding an index, they can seek to outperform it by adapting to market conditions and pursuing new opportunities as they emerge. And while you get the potential outperformance of an actively managed fund, you can still buy and sell it on your terms. Just like any other etf, markets can change in real time. Make sure your ETF can too. Learn more@fidelity.com ActiveETFs before investing in any exchange traded fund, you should consider its investment objectives, risks, charges and expenses. Contact Fidelity for a prospectus, an offering circular, or if available, a summary prospectus containing this information. Read it carefully. While active ETFs offer the potential to outperform an index, these products may more significantly trail an index as compared with passive ETFs. ETFs are subject to market fluctuation and the risks of their underlying investments. ETFs are subject to management fees and other expenses. Fidelity Brokerage Services LLC Member NYSE SIPC Known as the pioneer of Paso, Justin Vineyards and Winery produces exceptional wines perfect for enjoying this holiday season. Like Isosceles, their flagship Bordeaux style red blend, Justin Wines also offers unique and thoughtful gifts. Pick your wine, choose a box and add a personal message, icon or logo. You'll also find curated gift sets, library wines, magnums, even custom etched bottles. Start gifting today. Visit justinwine.com and use promo code money20 to receive 20% off your order for a limited.
- [01:55]
Jim Cramer
Hey I'm Kramer. Welcome to Mad Money. Welcome to Kramer. My friends, I'm just trying to make a little bit of money. My job is not just entertainment. To educate, teach you. Call me 173cbc tweet me at Jim Cramer so it was the government shutdown and some insane comments from OpenAI about a government backstop because of gigantic spending that caused a sell off? I think so. Now the shutdowns are almost over and Open Air is starting to learn about foot in the mouth disease. The averages come roaring back with the Dow gaining 382 points, S&P jumping 1.54% and the Nasdaq call going 2.27%. Housing pleasure best day for Texas May I'm not surprised this turned about. Why? Because I've learned to trust the market and not start betting against it because we had a tough week. As much as the stock market seems nuts, it's not as nuts as you think. That's what everyone who shorted the AI plays found out today. I know that there are Hedge funds that make fortune shorting the market in 2007 based on the quicksand of bundled real estate trash, there are hedge funds to question. It crushed it in the crash of 87 and stock valuations went sky high. I was one of them. There were many money managers who saw the COVID crash coming and sold as much stock as possible, then got short. They made out like bandits as long as they didn't overstay their welcome. And of course, there were people who shorted stocks, including me, that were.com bombs. And now the same short sellers, not me, because I can't sell, I don't own stocks are trying their hand at betting against the great data center build out, including its most visible winner, Nvidia, as well as the wild run in artificial artificial intelligence as examined by Palantir. The shorts think that because they were successful shorting one theme, they'll be successful shorting another. I say not so fast. Doesn't work like that. Nvidia Palantir, run by some of the smartest people in the world. Jensen Huang and Alex Carr. Are their stocks expensive? It depends. Nvidia stock has a reputation for looking expensive on forward earnings projections, then turning out to be inexpensive when we see the actual earnings and they come in better than expected. Yes, it's still growing that fast. Palantir is harder. Alex Karp seems like a renegade, but he really isn't. He's constantly trying to explain why his company's worth what it is. And he never stops crushing the expectations. I believe in Clark's leadership because you know what? I've been around. Hey, you know what? I started tech company myself, the street.com. all I wanted to do was to grow fast enough terrific operating margins like carp. Why? Because that's what every single investment bank and venture capitalist I talked to told me. I need it. We grew fast, but the profitability never caught up. So the company hung on for years and years. And here 25 got a hostile bid for almost nothing called the cash position. So my hat's off to Palantir. I wouldn't short that thing. Even after this run, I don't go out very much. But when I do in New York and it's not with my summit buddies who never talk stocks, people just want to ask me, why keep supporting Palantir, which when it was at 50, I said we'll go to 100. When it was at 100, I said it would go to 150. It was at 150, I said it was going to go to 200 and now I think it's going to 250 after this pit stop. 178 up to 193 hedge fund managers I meet almost all want to tell me, you know what you're you're dead wrong. Kramer. I don't feel very wrong, especially after talking to multiple clients who actually swear by Palantir. I wish the corp wouldn't put such a target on his back, but he's a crack shot. Soon as now I know the Palantir is richly valued at almost 300 times earnings as Karp says and I quote, this ascent has confounded many financial analysts and the chattering class, end quote. He goes on to say whose frame of reference did not quite anticipate a company of this size and scale growing in such a ferocious and unreal lenting rate, end quote. Then he gets a little too personal with the criticism. But in the end he points out, quote, palantir has made it possible for retail investors to achieve the rates of return previously limited to the most successful venture capitals in Palo Alto. To which I say amen. What do you want me to do here? Palantir and Nvidia are two of the biggest winners I've ever seen, and individual investors have indeed made fortunes in both of them. While money managers sat on the sidelines for the most part or shorted them. The ones that I've talked to, well, that talk to me. I don't talk to them. While Jensen Huang and Alex Karp have very different personalities, they both genuinely seem to care about the individuals and their shareholder base. And look, they've done an incredible job for you. I know this. I was in West Hollywood at a Total Wine and More this weekend signing my wife's mezcal bottles and many Nvidians showed up and let me see their statements that told me how much money they made. There were five grown men crying. My wife had to comfort them. That's because they had become in video millionaires. They never expected to make any real money in their lives. Coincidentally, by the way, I'll be signing copies of my new book, how to Make Money in Any Market. It's going to be at the Barnes and Noble on Atlantic avenue in Brooklyn, 6:30pm on Wednesday. I want to meet you. I want to sign your book. I want to take pictures with you. Barnes and Noble, Brooklyn, Wednesday, 6:30pm you need tickets? You can find the ticket link on X, also known as Twitter at Jim Cramer. Just just come see me. We so let's go full circle. Why did everything connected to the data center soar today. Simple, because if the companies that are building out their data centers stop doing so, they'll worry that they'll be left in the dust by competition. OpenAI Sam Altman will go after met his social media business, or go after Google search business, or go after Amazon's retail business. Maybe they'll pay Apple to be the default AI platform in the iPhone. OpenAI is already too big to fail and they can raise insane amounts of money because ChatGPT remains the best of the chat bots and Altman is an unlikely rainmaker. But how about the rest of the market? Here's why I didn't panic on Thursday or Friday when I was checking the tribal trust positions, endlessly bugging Jeff Marks, my co portfolio manager about what to do. I trust the market, you see. I believe in it. That's because as I say in how to make money in any market, it's never let me down in 43 years of investing. At a certain point it's empirical. Am I supposed to abandon the leadership and get out now because some short seller who was once right about something is arguing that artificial intelligence is now a house of cards? Look, we did have a problem, but not with AI. The problem was consumer confidence. We're close to Thanksgiving. We all saw the chaos at the airports. I got to the airport at 9 o', clock, I got home at 3:30. The problem is I was at the airport at 9am and I got home at 3:38am in other words, all nighter. Look, you get enough stories like what happened to me and people start canceling their Thanksgiving plans and hungry down and I don't blame them. I certainly would. That can ruin the holidays. It can certainly ruin our GDP growth for the holidays too. And that's a huge part of our economy. When we got signs that there could be finally an end to the government shutdown, the first one that seemed to cripple the economy because it went on for so long and politically shut down, practically shut down air travel. The money came boring that pouring back to the stock market. That's what happened today. Pretty obvious. There are so many companies involved in this datacenter build out which is the envy of the world except for China, which is doing it faster. I always complain that American experts are way too eager to give the Chinese government the benefit of the doubt over us. We assume that the Chinese Communist Party never makes any mistakes. But if they're building out furiously, are they doing something dumb? I don't think so. The bottom line with the Government potentially about to reopen. It's back to business as usual. And that means the data center stocks come roaring back, as they should. Even if you have zero faith in Silicon Valley, you should recognize that the Chinese are doing the same thing and respect that. All we are trying to do is keep up with them, and they're our number one competitor, and man, are they hard to beat. Let's go to Ian in Florida. Ian, Jim. How you doing? I am doing well. How are you? I'm doing excellent. Excellent. Congratulations on the book, Jim. Looking forward to getting mine signed in South Florida sometime soon. All right, come up to Barnes and Noble on Wednesday in Brooklyn. Six. I'll sign it. Let's go to work. What do we got? I'll see you there, Jim. I'm looking at a stock I wanted to start an entry in, definitely best of class, and it's almost like 20% down from its highs. And it's actually got a split coming in about a few days. It's Netflix. Yeah, I like Netflix aplenty. I think that Netflix understands exactly how to make a movie, how to make shows. They know what people want and, you know, what they really have. It's a subscription business. And I like, like Costco. I like, like, Spotify. Subscription businesses there for me. You know what? We're going to go to Shirley in Texas. Shirley. Hi, Jim. My question is, and I've enjoyed your knowledge and your show for many years now. Thank you, Shirley. That I've held Broadcom for several years. Is it a hold or sale? Hold or sell? Broad comes a buy. I mean, we're talking about. We're talking about Hawk Tan. He is major great. He's one of the greatest CEOs ever. And I think that the company is doing fabulously, and if anything, it's a big position. French Apple Trust, Joe in Indiana. Oh, my God, the Kings. The kings of football. Joe. Thank you, Mr. Kramer, and thanks for everything you've done for me. Of course, I have a stock that I keep hanging on to because it pays such a big dividend, but it just seems to keep going down on me. BlackRock. Okay, okay. Black. BlackRock. I think that BlackRock's pretty good. Now, it did have a dip here, and I like it. I'm gonna throw in Blackstone. I'm gonna go twofer. I like BlackRock. And I said, but I own BlackRock for the travel trust. I think Larry Fink is terrific. I want to buy that stock right here, right now. Okay. Today the market rallied because we got signs of the shutdown finally ending. That's all it took to bring the stocks back up too. Don't forget the data center is the greatest theme in this in this year of magical investing All Mad Money. Tonight, Amgen announced some very promising heart attack prevention results in the phase three trial of its drug Repatha, which I'm one. But what drug am I not on? So could the stock have more upside after this? Well, let's check with the CEO and then could D Wave Quantum be one of the I'm not on all the drugs. That was a joke. Could D Wave Quantum be one of the better players in the speculative quantum computing space? I'm getting the latest with the company's top risk and you know we've begun following the regional national story that is Dutch Bros and they have some coffee and believe it or not, I had a little this morning. I had a little right before the show. And I got to tell you some I'm feeling darn good even though I go to bed last night. But that's just the way it is when you have the Annihilator. Stay with Kramer.
- [12:27]
Show Producer/Host Assistant
Don't miss a second of Mad Money.
- [12:29]
Jim Cramer
Follow imKramer on X. Have a question? Tweet Kramer hashtag mad mentions. Send Jim an email to madmoneycnbc.com or give us a call at 1-800-743, CNBC.
- [12:43]
Show Producer/Host Assistant
Miss something?
- [12:43]
Jim Cramer
Head to madmoney.cnbc.com on Fox 1 now you can stream your favorite live sports so you can be there live for the biggest moments. Touchdown and catch history in the making. Fox one we live for live streaming.
- [13:03]
Commercial Announcer
Now Known as the pioneer of Paso, Justin Vineyards and Winery produces exceptional wines perfect for enjoying this holiday season. Like Isosceles, their flagship Bordeaux style red blend, Justin Wines also offers unique and thoughtful gifts. Pick your wine, choose a box and add a personal message, icon or logo. You'll also find curated gift sets, library wines, magnums, even custom etched bottles. Start gifting today. Visit justinwine.com and use promo code money20 to receive 20% off your order for a limited time. Hiring isn't just about finding someone willing to take the job. Count on Indeed sponsored jobs to find the right person with the right background who can move the business forward. Stop struggling to get your job post even seen on other sites. Give your job the best chance to be seen with Indeed's sponsored jobs. They boost your post for quality candidates so you can reach the exact people you want faster and it makes a big difference. According to Indeed data, sponsored jobs posted directly on Indeed are 90% more likely to report higher than non sponsored jobs. Plus, with Indeed sponsored jobs, you only pay for results. No monthly subscriptions, no long term contracts. Just a boost whenever you need to find quality talent Fast. Join the 1.6 million companies that sponsor their jobs with Indeed. Get a $75 sponsored job credit to help get your job the premium status it deserves@ Indeed.com MadMoney.
- [14:41]
Jim Cramer
In the last few weeks, the long dormant health care sectors finally started to show that a life it's so inexpensive, it's crazy. Take Amgen, the big biotech company with a host of drugs for cardiovascular disease, inflammation, oncology, all sorts of rare diseases. This Stock's up roughly 20% from its late September lows, quitting a monster on last week when Amgen reported spectacularly better than expected quarter. Then this past weekend, the company announced some very promising heart attack prevention results from a phase 3 clinical trial. Repatha, that's the cholesterol drug. So could this stock have more room to run? Now the health care sector seems to be back in style. Let's take a closer look at Bob Bradway, the chairman, president, CEO of Amgen, friend of the show. Get a better read of the quarter what comes next Friday. Welcome back to Bad money.
- [15:24]
Bob Bradway
Thank you, Jim. Pleasure to be with you.
- [15:25]
Jim Cramer
All right, so Bob, I think that people have to understand that there is no level of cholesterol that's good. That's something we've determined. But there's no way to get it down to the level that would make it. So it's insignificant except for with your drug.
- [15:42]
Bob Bradway
Well, Jim, I think what we've demonstrated with the data that we shared this weekend is that when it comes to preventing, for example, heart attacks, by lowering LDL to a target of 45, a median of 45, we were able to reduce by 36% the risk of a first heart attack in those subjects that we studied in this, in this trial. So there's a great deal of excitement as we're answering for the first time whether by adding Repatha on top of optimized therapy for those who are concerned about the risk of a heart attack or stroke or other major heart problem. We demonstrated that by adding Repatha on top of what was otherwise considered to be optimized therapy, that we could prevent those first occurrences again of a heart attack by 36%, prevent stroke, and even a strong signal suggesting we prevent cardiac death. So these are exciting data for the field. This trial answered questions that have been on the mind of investigators and physicians and patients for Some time. We've now unequivocally answered that when it comes to LDL cholesterol, lower is better. And that even to a targeted median, or an achieved median, rather, 45 were able to demonstrate meaningful benefit over what was otherwise seen in the placebo group. That was controlled on, just to emphasize the point, on what was previously considered optimal therapy for those patients.
- [17:07]
Jim Cramer
Look, I'm in that camp. I went, mine was around 60. I thought that I was fantastic. All I heard was it was good. And I immediately was prescribed Repatha. And I said, I don't want to take this shot every other week. It's ridiculous. My cholesterol is low. And my doctor explained to me that there is no level that is low enough. Now, are there people in your study who would. Doctors who would say, you know what? If I were a GP for anybody else, I would tell them, did you see the results of this? You got to take it. I mean, because I know you're not a doctor and you're not telling people, but wouldn't if you went to med school, wouldn't they study this and therefore, after they graduate, put people on this?
- [17:51]
Bob Bradway
Well, Jim, I think what the study does is it helps people appreciate that again, when it comes to LDL cholesterol lowers better. The sooner you get to the lower levels, the better. Especially for people, for example, who have diabetes or people who for other reasons are concerned about their risk of a heart attack or stroke. These trial data unequivocally suggest that that's a conversation that's worth having with your physician. So, again, we're excited about what these data represent for the future of reducing heart attacks and strokes in this country.
- [18:19]
Jim Cramer
I know that this is not something that I'm about to ask, a question that I know you can't point blank answer, but maybe you can help me see what they say, what people are saying. But my, my doctor said, okay, listen, by the way, this also lowers plaque in your brain. I said, well, that's impossible also be a study. Everybody would know that. And he said, well, we're prescribing it to people because we think it's right. We're doing a study. Is there really a nationwide study on plaque?
- [18:46]
Bob Bradway
Well, Jim, I'm not aware of any placebo controlled studies underway to evaluate that question. I think you're referring in particular to whether there's any benefit in Alzheimer's disease from these treatments. I know there's a lot of interest in that question, but I'm not aware of any placebo controlled studies. Underway to evaluate that.
- [19:03]
Jim Cramer
That is absolutely correct. That was what I'm taking it for, besides cholesterol. And my doctor expressed me said that this is it. This is the only one that they're having any success with. I don't want to, let's put this way, it's a miracle drug and I think people need to know that. Now a lot of people are going to spend most of the time talking about maritime. I think maritime can be big and it's going to be one of ultimately many. As I talked to Dr. Borro this morning. Can you give us an update of what we should be looking for, some data points?
- [19:35]
Bob Bradway
Sure, let me be happy to talk about that, Jim. But just before moving off of her path for a moment, let's not lose sight of the fact that the leading killer of people in the United States and all around the world is heart disease. And again, we know that 90, 99% of people who have a heart attack are have a modifiable risk factor. The biggest modifiable risk factor for those patients is level of ldl. Again, what we've demonstrated here is a very significant opportunity to reduce the risk of those first heart attacks by driving people down to a median LDL level of 45. So we're excited about what that represents.
- [20:08]
Jim Cramer
But I didn't mean to.
- [20:10]
Bob Bradway
The only thing I wanted.
- [20:11]
Jim Cramer
You're right. Look, you know, obviously I'm in your camp. I mean, there are a lot of people taking statins. They're not doing the job.
- [20:19]
Bob Bradway
For many people. They're not doing as everything that could be done to reduce the risk of those first events. The other thing Jim, I just want to point out is one of the things we did a few weeks ago in anticipation of being able to share these data are that we made the product available to people in the United States at $8 a day. So anybody who wants to go to amgen now.com can receive Repatha for $8 a day. Most patients, by the way, are paying much less than that out of pocket. But for those who are either uninsured or for whatever reason are buying this drug for, for cash, can now get it from amgenow.com at $8 a day. And when trump barex.com is available online, we'll be adding it there too. So the good news is this drug is available to American citizens at the lowest price available in any of the G7 countries. And again, it underscores our belief that this is a medicine that can benefit millions of patients around the nation. And we want Those who are appropriately eligible for this therapy to have access.
- [21:18]
Jim Cramer
It had been much higher price, right, sir?
- [21:23]
Bob Bradway
Yes. We have lowered the list price on Repatha twice now. The list price we lowered by 60% the list price to be able to make it available to patients for $8 a day.
- [21:34]
Jim Cramer
No, look, it's important. It just happens to be a day when. When Dr. Borla paid a lot of money for something that may or may not be, that is I think speculative versus maritime. So it's not prurient interest. It does make me. It's just important to ask you about.
- [21:51]
Bob Bradway
Sure. Well, maritide obviously is our molecule which is differentiated from what's available in the field today. We designed a long acting molecule that we're excited about for what it has demonstrated in its ability to reduce weight in people who are obese or living with overweight. And the therapy is rapidly enrolling in phase three clinical development reflecting the strong interest in the differentiated approach that we bring with Marathite. So in addition to what we're confident we'll be able to do for weight loss, we're also excited about what this represents for patients that have type 2 diabetes. The field has for many, many years been seeking to have a long acting type 2 diabetes medicine. We believe this will be dosed monthly or less frequent for both overweight as well as patients with type 2 diabetes. And when we look at the data that we've generated so far, we're also very excited about what it represents for other diseases like heart disease as we've been discussing. So we think this has the potential by virtue of what we've seen so far in its ability to lower blood pressure, to lower inflammation, to lower blood lipids, to also be an attractive therapy in the field of heart disease.
- [23:04]
Jim Cramer
Well, excellent Bob, and thank you for sharing with us the very important data that I think should change the way medicine is done in this country. I've said that to you off camera, might as well say it to you on camera. I want to thank Bob Bradway, CEO of Amgen. Thank you Bob. Good to talk to you.
- [23:18]
Bob Bradway
Thank you, Jim.
- [23:19]
Jim Cramer
This is a very big drug that's going to do many, many things and you should ask your doctor whether it's right for you. I know I sound like commercial. I don't care. Just want to save your life. Get money specific for the frame.
- [23:32]
Bob Bradway
Coming up, Cramer's getting to the bottom.
- [23:34]
Show Producer/Host Assistant
Of the hype around quantum computing with.
- [23:36]
Jim Cramer
One of the main players in the space next Fox News is now streaming live on Fox 1. The voices you trust the stories you won't find anywhere else.
- [23:48]
Christine Barone
This is the story breaking right now.
- [23:50]
Jim Cramer
Fox one we live for lives.
- [23:52]
Commercial Announcer
Try it free for seven days. Offers are subject to change. Go to Fox one for complete terms and conditions. Known as the pioneer of Paso, Justin Vineyards and Winery produces exceptional wines perfect for enjoying this holiday season. Like Isosceles, their flagship Bordeaux style red blend, Justin Wines also offers unique and thoughtful gifts. Pick your wine, choose a box and add a personal message icon or logo. You'll also find curated gift sets, library wines, magnums, even custom etched bottles. Start gifting today. Visit justinwine.com and promo code money20 to receive 20% off your order for a limited time.
- [24:34]
Jim Cramer
Over the past few weeks. This once read out speculative size market. You know it's getting crushed. I mean just look at the quantum computing place. We had D Wave Quantum on the show in August, Stock was at 18 and changed by mid October and it peaked at nearly 47 bucks. But now I think this makes sense to somebody is back below 30, down almost 40% from that high. That's where you got to start thinking about getting in. Last week D Wave reported third quarter results and the report was really a perfect example why these stocks are so tough to gain. On the one hand the numbers were all better than expected. On the other hand, they only had 3.7 million in revenue last quarter because the technology still in its infancy, stock actually rallied almost 4% response still finished last week down nearly 20%. Remember last was bad stock, bad week for these stocks. So what the heck do we do with the thing? Are we witnessing a buying opportunity here or is the stock still overheated? Given that it still remains up to almost 250% for the year, let's take a closer look at Dr. Alan Barrett. She's the President CEO of D Wave Prime. To find out. Hey Doctor, welcome back to Man Money. Hi Jim.
- [25:31]
Show Producer/Host Assistant
It's a pleasure to be speaking with you again.
- [25:33]
Jim Cramer
All right. So Alan, I think I don't want to bury the lead here. You have had this quarter, the one that we are in right now, a huge amount of business. The 2.4 last you were already up to 12 million. So something's really going on. You are beginning to get some big orders from people who know how to use your product and are doing things substantively with them, correct?
- [25:56]
Show Producer/Host Assistant
That's absolutely right. We've had an amazing year so far this year as we're starting to see both our system sale business grow as well as our cloud based quantum compute as a service business Grow.
- [26:11]
Jim Cramer
Now we are starting to talk about situations like I'm just going to mentioned some Japan, the tobacco, which people may not realize has a medical arm and is using you.
- [26:26]
Show Producer/Host Assistant
That's correct. And Japan tobacco is a really interesting example because this is the first time that a quantum computer is being used for AI model training. Basically what Japan Tobacco has done is used our quantum computer to train their large language model for discovery of new molecular structures. And what they're finding is that by using our quantum computer, they are able to generate better structures faster with less power consumption. And when I say better structures, I mean more well suited to human drugs. And this is really important because I think we all know that quantum is going to be a really important component of AI. And this is the first time that anybody has ever been able to use a quantum computer for a commercial AI application.
- [27:18]
Jim Cramer
Now also, and I don't want to, I should spend more time on them. I know, but there's some other customers. People realize how important this is. Huge customer win October is Swiss quantum technology. Now this again is a huge agreement for you. And it just happened. I don't know what say where, where it is right now, but what and what they're doing with it, but it's obviously very big.
- [27:40]
Show Producer/Host Assistant
Yeah. So basically this was a deal to provide 50% capacity of one of our quantum computers in support of Italy's digital transformation initiative. So they acquired 50% capacity of our system for 10 million euros. The system will be placed in the Lombardi, Italy region. And then we will be working together with the Italian government and a new consortium called Q Alliance to basically train a quantum workforce in Italy to do new research leveraging our quantum computer and to explore commercial applications.
- [28:24]
Jim Cramer
Now, one of the things that I find hard, and you indicate you actually touch on this in your conference calls, is everyone claims they're the best. I mean, for instance, there's a company called Quintinium. I know this was I my chapter Sons Honeywell, which says as a full stack offering, Helios, which is their current one, is one of the most advanced commercial quantum computers today. And I read that and I say, well, I don't know, are they ahead of D wave? Are they behind? How do we gauge things?
- [28:53]
Bob Bradway
Yeah.
- [28:54]
Show Producer/Host Assistant
So first of all, Jim, D Wave is quite unique in the quantum industry and that we are developing to bring to market both of the main architectural approaches to quantum computing. They're called annealing and gate, and they're each good for solving different types of problems. So if you've got a problem that requires Annealing healing, we've got you covered. If you've got a problem that requires gate, we've got you covered. That makes us the only quantum computer computing company in the world that can address the full market for quantum. Now second, we use superconducting technology and we believe that at the end of the day, superconducting will win. And the reason is speed. Superconducting quantum computers are a thousand times faster than any other mode of quantum computing. So faster than trapped ion, which is what quintinuum uses, faster than photonic, faster than neutral atom. So why would you ever want a quantum computer that's a thousand times slower? You wouldn't. That's why superconducting at the end of the day is going to win. And finally, our annealing quantum computers are the only ones in the world that have been able to solve a real world problem that can't be solved classically, what we call quantum supremacy. And that makes us quite unique in the industry. No other quantum computer today is able to do even a little bit better than classical, let alone solving problems that classical cannot solve. But our quantum computers have achieved that goal. And then of course, we've got customers that are using us as a part of their business operations. We talked about Japan Tobacco. This quarter we announced basf, Large chemical Company, North Wales Police. So we are commercial today with our quantum computers and that makes us very different from everybody else.
- [30:55]
Jim Cramer
I will say that, that Arvind Christian might disagree. The CEO of IBM has told me that he has commercial quantum computing and I think he's a good guy.
- [31:07]
Show Producer/Host Assistant
I'm glad you brought that up. What you need to do is ask those customers what they're actually doing with the IBM quantum computer. Are they doing research experimentation or are they solving business problems as a part of their business operations? I think you'll find they're doing research experimentation because those quantum computers are not yet at the point where they can solve commercial problems at scale. Only D waves annealing quantum computers have reached that point. And you should go talk to our customers. In fact, we have a yearly customer conference. It's called Cubits. Our next one is in Boca Raton at the end of January. And I invite you to come out, be there. You can hear from our customers about all the things that they're doing. You can quarter them and talk to them one on one. And I want to do what they're doing with.
- [32:00]
Jim Cramer
I want to do this. I believe in the technology. Now people going to say you believe in going to Boca Raton because You were there for the last four years in January. That is not the reason I want to go. But I got to tell you Alan, I think that this is very good because you know, I believe in technology. The stocks come down really big so it's not like people are buying at the top. And I really appreciate you explaining us what you're seeing and what you're doing. Alan Baratz is the president CEO of D Wave Quantum. Thank you Doc. Really appreciate it. Thank you that much. Back here for the break. Coming up, is now the right time to start brewing a position in Dutch Bros. Kramer sitting down with the CEO of the west coast coffee chain next. Look, I've been up all night because I flew back when some red eye supposed to be in at 11 in the morning. I got in at 3am and the only thing is saving me is this drink. You know what this drink is? This is the Dutch Brothers, Oregon based drive through coffee chain drink that is going to keep me awake right through the Eagle scheme this time. The company just reported a nice top bottom line beat stock got hit the next day. That was wrong. Sold off 4.2%. That was wrong. Mainly because Dutch Bro saw its shop level margins come in a little bit light. But that's ridiculous. After the initial pullback on Thursday, this thing rallied on Friday. And then of course it was really were today as it should have, surging 6%. It's almost like Wall street revisited the quarter and realized it was a good one upon further review because people just don't understand the stock or the company or the drink. So let's check in with Christine Barone. She's the presidency of Dutch Brothers. Get a better sense of the quarter and what's happening. I'm not talking as fast because I've had the drink because I haven't had enough. But the fact is that this is something that worked in Oregon and it's working around the country.
- [33:53]
Christine Barone
It is working around the country. We had an awesome quarter. Quarter. Our same shop sales were up 5.7% and our customers are loving what we're doing.
- [34:02]
Jim Cramer
That's a blended average. The ones that you own were even better.
- [34:05]
Christine Barone
Yeah, we had a great, great quarter. So our company owned same shop sales were up even more and they were up at 7.4%.
- [34:13]
Jim Cramer
Now you are in half the states in the country. Is there a state where it's not working? No.
- [34:18]
Christine Barone
We have been well received everywhere we're going. So really excited to continue to expand. We opened a number of new states this year. We're up to 24 states now and just about 1081 shops. We ended the quarter with I like.
- [34:33]
Jim Cramer
A situation where there's a roadmap. How many do you think you can handle in this country?
- [34:37]
Christine Barone
Well, we are total addressable market that we shared an investor day is about 7,000 shops. So we have a long way still to go.
- [34:44]
Jim Cramer
How expensive is it these days to find help to be able to build new stores?
- [34:48]
Christine Barone
So we are finding real success as we open new shops. We have developers help us as well and we have had no problem finding new shops and opening new shops.
- [34:59]
Jim Cramer
Now I want people to understand that if I go, you're going to find new drinks all the time. It's not like there's just the same menu. What am I going to see for the holidays?
- [35:08]
Christine Barone
Well, we have all kinds of great new drinks for the holidays and some of them are returning. We do have a wonderful holiday cookie that is a new drink. You can get it across lots of different platforms. So I had one the other day with protein milk.
- [35:24]
Jim Cramer
You have the edge on me. It seems like that young consumers, Gen Z have discovered you and I'm trying to figure out what they think, what draws them, what is it that's different, what are they excited about?
- [35:37]
Christine Barone
Yeah. So as we look at our customers, it's really a full experience that you get at Dutch Bros. And so when you come through our drive thru, our broistas just love to engage our customers. They love to have a little conversation with them. They love to remember them and their names. And so I think that not only do you get an awesome drink, but you also get that conversation.
- [35:58]
Jim Cramer
Now there was a period where it was hard to find works. Now you, no problem you, you're getting good young people to man the ship.
- [36:06]
Christine Barone
Yeah. So we have great brewistas and that's really where the brand starts. And it's all about our people and they want to come work in the environment. We have great music on that we're playing. You get fun drinks while you're there and you're working with a wonderful group of people where we invest a lot in training. So you're working alongside someone who's really trained up and knows what they're doing.
- [36:26]
Jim Cramer
Now there are whole parts of the country you that do not have Dutch Bros. Correct?
- [36:30]
Christine Barone
Correct. We have a long way still to go.
- [36:33]
Jim Cramer
So where are you under stored? Is it in the Midwest or is it up here? Because a lot of people, I think that if you open one in New York, the stock go up 20 bucks.
- [36:42]
Christine Barone
Yeah. So we, we have Lots of shops still to go. We don't have any yet in the Northeast. We just opened our first one in Illinois. But even in the markets where we've been for a long time, we still have a lot of great growth ahead of us.
- [36:55]
Jim Cramer
Now. What do you. What is. I'm trying to figure out what your loyalty plan is these days because this is something that you have brought in. You've also brought an app ordering momentum. It sounds like everything's going. These are all your specialties and they're working.
- [37:08]
Christine Barone
Yeah. So we launched mobile order in Q4 of last year. We're now at 13% penetration in mobile orders. That's really pretty CO even and it could, could go higher. What we want is we want our customers to order in whatever way they want. And so that channel was clearly something that was popular with a lot of customers. That's providing a really awesome on ramp to our Dutch rewards program, which is now at 72% of transactions. So very high. We can have conversations with our customers. They get a lot of value out of that rewards program.
- [37:43]
Jim Cramer
There are a lot of people say, look, Jim, you like Starbucks. You can't like the stock. You can't like that. And it seems I like touch Pros. I think that's stupid. Would you agree that there's room for everybody?
- [37:54]
Christine Barone
I think this is a really large and growing market and half of our beverages are coffee, but half are energy and other types of drinks like lemonades and teas. So we're really the. The category creator of the customized energy drink.
- [38:08]
Jim Cramer
Now, do you think that there really is a move away from alcohol? And the reason where I'm going here is, is that only a mocktail to me is like some of your drink. I happen to like mocktails. I don't drink a lot of alcohol and they seem like that they are. You're creating new drinks that are like mocktails for the Gen Z people who don't seem not to like to drink that much.
- [38:30]
Christine Barone
Well, I love mocktails as well. And I would share that. I think what it is is really as Gen Z is coming into this market, they loved US iced. They love customized and creating their own drink. And so we have a whole plethora of drinks that you can choose from, but we also will work with you to customize it for yourself. And I think that's what's really working.
- [38:49]
Jim Cramer
Absolutely. Now, Christine, one of the things that I'm getting tired of it, but I know all the restaurant stocks, they're all down big and that's because people feel the American consumers fed up with inflation doesn't have the money. I look at your numbers and I think maybe the American consumer just wants to to be entertained and have a good time with a drink with some with food and that you're more than just a liquid.
- [39:11]
Christine Barone
I think that we all need something to brighten our days and when you come through our drive thru I think that's just what we do is that we celebrate with you, we give you a great drink, we listen to what's going on in your life and I think that all of those things are just incredibly important right now and having that little bit of connection is something that makes our days better.
- [39:30]
Jim Cramer
Okay. Now I know people who don't have one think that what you just heard is fanciful. Having experienced it, I will tell you it's spot on. Christine Barone, the presidency of Dutch Bros. Thank you, Christine.
- [39:42]
Christine Barone
Thanks, Jim.
- [39:43]
Jim Cramer
Everybody's back here for the break. It is time, it's time for the lighter up. Welcome back. Rapper in the morning. It's heavy stock 7 by Mike's also census. If you go to another course to the party you're playing it Sam and then the lightning round is over. Are you ready? Steve Decks. All right, we can't Monday. Let's start with Chase in Illinois. Chase. Hey Jim, it's Charlie from Chicago. I'm a longtime listener, looking forward to getting your insights. I know you don't like companies that are pre revenue but a recent IPO that has come across my radar is a financial security company. This technology has the potential to save Swiftbanks over $40 billion a year and has applications in the post quantum world. Stablecoins, defense contractors, gambling industry and payment processing. We'd love to hear what you think about the ticker btq. Thanks, Jeff. Okay, look, I think that that's going to be yours. That's a speculation for you if you're going to speculate in quantum for me it's going to be D wave. It's not necessarily the best there is in terms of because I really believe believe in IBM's quantum and but I will say that D wave is my choice. Let's go to John and Massachusetts. John. Hey Kramer, how they hand tonight? All right, what's up? One of your old favorites, Mr. Myers. I understand you kind of were thinking about changing your mind, backing off on it because I got to tell you I'm trying to see some good news in this that I was really all in on and I'm not getting that news yet. And the stock is Telling me I'm wrong. I don't like a stock telling me I'm wrong and not listening. Because you know what? Even though I got a problem with hearing, I can hear the footsteps of the people leaving Bristol Myers. So that's what I feel about it, is in the Chapel Trust. Big meeting on Thursday. We'll have to suss it out a little. Charlie in Georgia. Charlie. Hey, Jim. Thanks for taking my call from beautiful Lake Oconee, Georgia. Been a long time follower, my friend. Thank you. My question's regarding Baidu. Baidu's good. Baidu's good. Baidu and Alibaba are good. Now, they have moved. They have moved a lot. Baidu's up 56%. But if you're going to own Chinese stocks, you want to own Alibaba first and Baidu second. And I want to go down to Georgia bad. Let's go. Oh, let's go to Georgia, Massachusetts. Not the same thing. George.
- [42:05]
Bob Bradway
George. Hi, Jim.
- [42:08]
Jim Cramer
George, I've been thinking about buying stock in Brinker International. I think it's the right level to buy Brinker, but you have to understand, 10 times earnings does matter, but the restaurant group is radically out of fashion. So if you're going to buy some. Let's say you want to buy 100 shares, you buy 25 here, and then you have to wait. I will not sanction buying more at this level. Let's go to Mike in Georgia. Mike, my bike. Booyah. Love everything you do. The club, the books, the show. Thank you. For some reason, though, I didn't take.
- [42:38]
Bob Bradway
Your advice on the stock a couple.
- [42:40]
Jim Cramer
Weeks ago, and I've been taking a terrible beat down ever since. What in the world can I do with United Rentals at this point? You can hold your rent. That was just all people turning on the data center. They heard that Sam Altman and OpenAI was spending too much money and people were saying, woe is me, data center. So that's come down to level or now. I think it's okay. Let's go to Jim in New Jersey. It could be me talking to myself. Jim. Hey, Mr. Kramer. How you doing, buddy? All right, neighbor. How you? I'm all right. Sometimes I was called the Mid east eel man when I was stationed overseas. But listen, I even watched you back then, buddy, when you had hair and you were across, sitting across from Mr. Ludden. LUDW. Okay, I remember you back then. Yeah, that's true. So you're a great guy in my rag. Who's good? I like Wagyu. I got Rigatoni I got Ragu and Tony. Can you believe it? These two knuckleheads. How can I help you? I love you, man. You broke tomatoes and you had a dog named Ragu. Why not? Hey, because you're. You're from the northeast, man. You're northeast guy. Done your way. Done your way, partner. How can I help? All right, because of you, I get to watch you in the morning and at night, because of you, buddy, I've got a great retirement. Now what I need to know is I like a little speculation, okay? And there is a company down in Texas where they grow the big guitars. Like Steve Miller says, it's called N U A I. Well, man, you know what? I'm a joker and I'm a toker. But I'm going to tell you, I like Lindy even more. But if you, if you want your spec to be that, I am going to bless it. And I'm speaking with the pompous of love. And that, ladies and gentlemen, is the conclusion of the Lightning Round.
- [44:24]
Show Producer/Host Assistant
The Lightning Round is sponsored by Charles Schwab.
- [44:38]
Jim Cramer
There's room for more than one winner in this race for GOP1 weight loss supremacy. But some of these winners are going to be bigger than others. This morning, the gang on the squawk on the street grilled Pfizer CEO Dr. Albert Bourla about his company's $10 billion acquisition of Matsara. A drug company is working on a monthly GOP dash. One shot. Pfizer is paying $65.60 per share upfront plus contingent payments of $20.65 per share tied to specific milestones. You might wonder why Pfizer would bother moving into a market that's now owned by Eli Lilly, which I think has beaten back Danish Novo Nordisk maybe even into submission. April Lilly's on the market with a very effective once a week shot. But more important, soon that have a pill version. It could be gigantic. People hate shots. No wonder Lilly's Stock voted nearly 5% today. On the verge of becoming like the first non tech stocks to cross into the $1 trillion circle besides Berkshire Hathaway. But I say not so fast. As much as I like Lilly for the Chapel Trust, where it is a very big position and we're not a seller. I'm mindful that you can't take anything for granted in this business. Take cholesterol, which we talked about earlier with amgen back in 1987. Merck invented the whole class of statins, the first drugs to truly lower cholesterol after it was definitively linked to heart attacks. Merck's Methicorp was not an immediate sensation. But then it took off and became a billion dollar drug. I made a fortune betting on that one in the 80s. But eight years later, Warner Lambert developed another statin. Lipitor initially wasn't perceived to be much of a rival, but then in 2000, Pfizer bought Warner Lambert for $90 billion. And that was in large part because it needed a blockbuster and boy did it ever get one. In the early 1990s, Merck turned its focus to a new statin called Zocor. But that drug sales peaked in 2002 at 5.6 billion. Pfizer's Lipitor peaked at 12.9 billion in sales in 2006. One of the best selling drugs of all time, Lipitor was more powerful and could be taken at any time. While Merck, still core of money restrictions, wasn't as effective. Can Pfizer win again in the GOP Dash 1 space? Look, the company it just put Medsura has a shot that only needs to be taken once a month instead of once a week like Lilly, but it doesn't have the efficacy of Lilly shot yet. Given that people historically hate to take shots and many eventually stop taking the injections, a once a month dosage seems terrific idea to me. But Lilly's spending a fortune to develop a pill form of the drug that you can take every day like any other medication and that could be more popular than any shot. You're much more likely to stick with a pill than an injection. Plus, one of the biggest drawbacks with the current GOP1s is that they cause you to lose fat and muscle in equal measure. These drugs make you thin, but they make you weaker. However, Louis working on a shot that's more targeted. It will attack fat to muscle at a 3 to 1 ratio. Still, I think Pfizer is very smart to buy Medsara in order to get a piece of the GOP Dash 1 pie. Even if it takes three years to be approved and who knows how much time to scale the needed factories to but it could have another Lipitor on its hands. And even if this isn't Lipitor part two, it's definitely worth $10 billion to get into what may be the biggest class of drugs ever sold. I like to say, as always, bull market somewhere. I promise you just be right here at Man Botany. I'm Jim Kramer. See you tomorrow.
- [47:45]
Commercial Announcer
All opinions expressed by Jim Cramer on this podcast are solely Kramer's opinions and do not reflect the opinions of CNBC, NBCUniversal, or their parent company or affiliates, and may have been previously disseminated by Kramer on television, radio, Internet, or another medium. You should not treat any opinion expressed by Jim Cramer as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Cramer's opinions are based upon information he considers reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Mad Money disclaimer, please visit cnbc.com madmoneydisclaimer the holidays are the most wonderful time of the year. To save with Rakuten, use Rakuten to get cash back on gifts for everyone on your list. From toys to kitchen gear to electronics. Cash back is automatically added to your account and you can get paid with gift cards, PayPal or check. Join for free today and get a new member bonus after minimum qualifying purchases. Go to rakuten.com, download the app or install the browser extension. That's R A K U T E N Terms and conditions apply.